Navigation Links
Study of gene transfer for erectile dysfunction shows promise

80 years old with a mean age of 59. Six subjects were white, four were black and one was Hispanic. In half of the subjects, the cause of ED was diabetes or cardiovascular disease ?both of which can interfere with the ability of smooth muscle cells to relax.

The primary goal of the study was to determine the safety and tolerability of the new therapy. However, the results also showed that at the highest doses, men reported highly significant improvements in erectile function.

The DNA segments ?mixed into plasma ?were injected into the corpus cavernosum, expandable tissue along the length of the penis that fills with blood during erection. A variety of clinical and laboratory tests were used to assess safety. In addition, effectiveness was measured using the International Index of Erectile Function scale, a questionnaire that is commonly used to measure ED. Patient responses were validated by their partners.

Researchers identified no safety issues with the treatment. Participants who received the highest two doses had apparent sustained improvements in ED as measured by the questionnaire. The researchers said that a larger study that includes a "control" group treated with a placebo is needed to confirm the safety and effectiveness of the treatment.

Other researchers on the project were Melman, Natan Bar-Chama, M.D., with Mount Sinai School of Medicine, Andrew McCullough, M.D., with New York University School of Medicine, and Kelvin Davies, Ph.D., with Albert Einstein College of Medicine.

The technology is being developed by Ion Channel Innovations (ICI), a development stage biotechnology company, in which Christ and Melman are co-founders and directing members. The therapy is known as ion channel therapy because the proteins it targets are potassium channels, "gates" within cells critical for contraction and relaxation of smooth muscle.

At the Wake Forest Institute for Regenerative Medicine, Christ is con
'"/>

Source:Wake Forest University Baptist Medical Center


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study gene transfer for erectile dysfunction shows promise

(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... - The meters-long, carnivorous "shrimp" from hell that once ruled the ... a real softy, it turns out. A new 3-D modeling of ... parts were not hard like teeth, but flexible, shows that the ... of trilobites and other such creatures of the early seas. ...
... Environmental Pollution " details successful experiments at the ... the abiotic (non-biological) transformation and absorption of four ... these estrogen hormones by more than 80 percent ... since it could point to inexpensive treatment technologies ...
... courses of antibiotics can leave normal gut bacteria harbouring ... treatment, say scientists writing in the latest issue of ... researchers believe that this reservoir increases the chances of ... survival and suggesting that the long-term effects of antibiotic ...
Cached Biology News:Earth's first great predator wasn't 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3Antibiotics have long-term impacts on gut flora 2
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... through non core divestitures - , - Caliper signs ... , - Non-cash restructuring and goodwill impairment charge ... Caliper Life Sciences, Inc. (Nasdaq: CALP ), today ... 2008. Fourth quarter revenues were $36.7 million, a decline ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company,) (NYSE: ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product Endu ... and fiscal year ended December 31, 2008. , , ... revenue increased to RMB 466.9 million (US$68.4 million) for ...
Cached Biology Technology:BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 3Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 4Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 5Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 6Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 7Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 8Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 9Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 10Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 11Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 12Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 13Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 14Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13
Lingo-1 (K-13)...
HIF-1 beta (ARNT1) Purified Anti-Mouse, Anti-Rat, Anti-Human clone 29, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: